Amgen Receives Positive CHMP Opinion To Extend Indication Of Kyprolis® (Carfilzomib) For The Treatment Of Relapsed Multiple Myeloma
Pivotal Head-to-Head ENDEAVOR Study Shows Kyprolis Plus Dexamethasone Doubled Progression-Free Survival Compared to Velcade® (Bortezomib) and Dexamethasone
THOUSAND OAKS, Calif., May 27, 2016 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency has adopted a positive opinion to extend the current indication for Kyprolis® (carfilzomib) to include treatment in combination with dexamethasone alone for adult patients with multiple myeloma who have received at least one prior therapy.
"In the first ever comparative Phase 3...
Source: Amgen News Release - May 27, 2016 Category: Pharmaceuticals Tags: Uncategorized Source Type: news
TJP1 protein may identify multiple myeloma patients most likely to benefit from proteasome inhibitors
A gene known as TJP1 (tight junction protein 1) could help determine which multiple myeloma patients would best benefit from proteasome inhibitors such as bortezomib, as well as combination approaches to enhance proteasome inhibitor sensitivity, according to a study. (Source: ScienceDaily Headlines)
Source: ScienceDaily Headlines - April 28, 2016 Category: Science Source Type: news
TJP1 protein may identify multiple myeloma patients most likely to benefit from proteasome inhibitors
(University of Texas M. D. Anderson Cancer Center) A gene known as TJP1 (tight junction protein 1) could help determine which multiple myeloma patients would best benefit from proteasome inhibitors such as bortezomib, as well as combination approaches to enhance proteasome inhibitor sensitivity, according to a study led by the University of Texas MD Anderson Cancer Center. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - April 28, 2016 Category: Cancer & Oncology Source Type: news
The U.S. Throws Out $3 Billion In Cancer Drugs Every Year
(Reuters Health) - U.S. doctors and hospitals throw out almost $3 billion (roughly 2.7 billion euros) in unused cancer drugs each year because the medicines come in supersized single-use packages and excess medicine must be discarded for safety reasons, a recent paper suggests. Researchers focused on 20 expensive medicines that are given by injection or intravenous drip and require doses adjusted based on the patient’s body size. Often, the packages contain much more medicine than patients need, and the leftovers wind up in the trash. Even when much of the medicine goes in the garbage, patients pay for the ...
Source: Science - The Huffington Post - March 28, 2016 Category: Science Source Type: news
Tx Trio Ups PFS in Heavily Pretreated Myeloma (CME/CE)
(MedPage Today) -- Farydak-Velcade-dexamethasone combo confers 8-month survival advantage (Source: MedPage Today Hematology/Oncology)
Source: MedPage Today Hematology/Oncology - February 16, 2016 Category: Hematology Source Type: news
FDA Approves New Kyprolis® (Carfilzomib) Combination Therapy For The Treatment Of Patients With Relapsed Or Refractory Multiple Myeloma
Pivotal Head-To-Head ENDEAVOR Study Shows Kyprolis and Dexamethasone Doubled Progression-Free Survival Versus Velcade® (Bortezomib) and Dexamethasone
Kyprolis Label Expansion Represents Critical Advancement for Patients With Relapsed or Refractory Multiple Myeloma, Offering New Option For Backbone Therapy
Approval Expands Kyprolis Indication and Converts Monotherapy Indication to Full Approval
THOUSAND OAKS, Calif., Jan. 21, 2016 /PRNewswire/ -- Amgen (NASDAQ: AMGN) today announced that the U.S. Food and Drug Administration (FDA) has approved the supplemental New Drug Application (sNDA) of Kyprolis® (carfilzomi...
Source: Amgen News Release - January 21, 2016 Category: Pharmaceuticals Tags: Uncategorized Source Type: news
Medical News Today: Benefits of carfilzomib in multiple myeloma persist across subgroups
New research shows the benefits of adding carfilzomib to dexamethasone, compared with adding bortezomib, persist regardless of age, cytogenetic risk status or prior therapy. (Source: Health News from Medical News Today)
Source: Health News from Medical News Today - December 16, 2015 Category: Consumer Health News Tags: Lymphoma / Leukemia / Myeloma Source Type: news
New Analyses Presented At ASH 2015 Demonstrate The Potential Of Kyprolis® (Carfilzomib) As Backbone Therapy In Multiple Myeloma
Data Confirm Efficacy and Safety of Kyprolis Combination Across Range of Patient Populations
THOUSAND OAKS, Calif., Dec. 5, 2015 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced the presentation of new key data evaluating Kyprolis® (carfilzomib) -based regimens in patients with relapsed multiple myeloma. The data showed Kyprolis in combination with dexamethasone significantly extended disease progression compared to bortezomib plus dexamethasone across a range of difficult-to-treat populations, specifically those with high risk and previously treated disease. The analyses were presented during the 57th Annual Meet...
Source: Amgen News Release - December 5, 2015 Category: Pharmaceuticals Tags: Uncategorized Source Type: news
Pivotal Head-To-Head ENDEAVOR Study Results Published in The Lancet Oncology Demonstrate Superiority of Kyprolis® (carfilzomib) Combination Over Velcade® (bortezomib) Combination
Kyprolis Plus Dexamethasone Doubled Progression-Free Survival to More Than 18 Months Versus Velcade Plus Dexamethasone in Patients With Relapsed Multiple Myeloma
First Head-to-Head Study Comparing two Proteasome Inhibitors
THOUSAND OAKS, Calif., Dec. 5, 2015 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced that The Lancet Oncology published results from the pivotal Phase 3 head-to-head ENDEAVOR study comparing Kyprolis® (carfilzomib) plus dexamethasone to Velcade® (bortezomib) plus dexamethasone in patients with relapsed multiple myeloma. The data showed that patients treated with Kyprolis plus dexamethasone a...
Source: Amgen News Release - December 5, 2015 Category: Pharmaceuticals Tags: Uncategorized Source Type: news
New Analyses Presented At ASH 2015 Demonstrate The Potential Of Kyprolis® (Carfilzomib) As Backbone Therapy In Multiple Myeloma
Data Confirm Efficacy and Safety of Kyprolis Combination Across Range of Patient Populations
THOUSAND OAKS, Calif., Dec. 5, 2015 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced the presentation of new key data evaluating Kyprolis® (carfilzomib) -based regimens in patients with relapsed multiple myeloma. The data showed Kyprolis in combination with dexamethasone significantly extended disease progression compared to bortezomib plus dexamethasone across a range of difficult-to-treat populations, specifically those with high risk and previously treated disease. The analyses were presented during the 57th Annual Meet...
Source: Amgen News Release - December 5, 2015 Category: Pharmaceuticals Tags: Uncategorized Source Type: news
Amgen Submits Application In Europe To Expand Indication Of Kyprolis® (carfilzomib) For The Treatment Of Relapsed Multiple Myeloma
Application Based on Pivotal Head-to-Head ENDEAVOR Study Showing Kyprolis Plus Dexamethasone Doubled Progression-Free Survival Compared to Velcade® (Bortezomib) Plus Dexamethasone
THOUSAND OAKS, Calif., Dec. 5, 2015 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced the submission to the European Medicines Agency (EMA) of a Variation to the Marketing Authorization Application (MAA) to expand the indication for Kyprolis® (carfilzomib) in combination with dexamethasone for the treatment of adult patients with multiple myeloma who have received at least one prior therapy.
The application is based on results from t...
Source: Amgen News Release - December 5, 2015 Category: Pharmaceuticals Tags: Uncategorized Source Type: news
Triple Drug Combination Beats Standard Treatment in Myeloma Trial
A SWOG trial shows bortezomib, lenalidomide, and dexamethasone delays recurrence and lengthens life for myeloma patients, indicating a possible new standard of care. (Source: International Myeloma Foundation)
Source: International Myeloma Foundation - December 5, 2015 Category: Hematology Source Type: news
Addition of bortezomib statistically enhanced the PFS and OS in previously untreated MM
Dr. Brian Durie discussed the randomized phase 3 SWOGG S0777 trial that investigated the addition of bortezomib to lenalidomide and dexamethasone for previously untreated multiple myeloma patients without an intend for immediate autologous stem cell transplant. (Source: International Myeloma Foundation)
Source: International Myeloma Foundation - December 5, 2015 Category: Hematology Source Type: news
